Skip to main content

Androgens in human breast carcinoma

Medical Molecular Morphology volume 43, pages 75–81 (2010)Cite this article

Abstract

Sex steroids play important roles in the development of human breast carcinoma. Androgen receptor (AR) is expressed in a majority of breast carcinoma tissues. However, the significance of androgen actions remains largely unclear in breast carcinoma, differing from estrogen actions. Therefore, in this review, we summarized recent studies on androgens in breast carcinoma. Concentration of a potent androgen, 5α-dihydrotestosterone (DHT), was significantly higher in breast carcinoma tissue than in plasma, and DHT is considered to be locally produced from circulating androstenedione by 17β-hydroxysteroid dehydrogenase type 5 and 5α-reductase. On the other hand, aromatase was recently reported as a negative regulator for intratumoral DHT production by possibly reducing the precursor testosterone. Androgens predominantly show antiproliferative effects in breast carcinoma cells, but association between AR status and the clinical outcome of the patient remains controversial, perhaps partly because AR status does not necessarily reflect androgenic action in breast carcinoma. Recently, molecular apocrine breast carcinoma was identified by microarray analysis. Molecular apocrine carcinoma was characterized by being estrogen receptor (ER) negative and AR positive and by being associated with increased androgen signaling and apocrine features. Therefore, androgenic actions may also be involved in apocrine features in breast carcinoma.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S (1992) Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18:112–118

    PubMed  CAS  Google Scholar 

  2. Isola JJ (1993) Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 170:31–35

    Article  PubMed  CAS  Google Scholar 

  3. Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, Look MP, Liem GS, Klijn JG, Henzen-Logmans SC (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A:1560–1565

    Article  PubMed  CAS  Google Scholar 

  4. Brys M, Wojcik M, Romanowicz-Makowska H, Krajewska WM (2002) Androgen receptor status in female breast cancer: RT-PCR and Western blot studies. J Cancer Res Clin Oncol 128: 85–90

    Article  PubMed  CAS  Google Scholar 

  5. Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer (Phila) 98:703–711

    Article  CAS  Google Scholar 

  6. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, Sakurai K, Inoue T, Nishiguchi Y (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 13:431–435

    Article  PubMed  CAS  Google Scholar 

  7. Burnstein KL (2005) Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 95:657–669

    Article  PubMed  CAS  Google Scholar 

  8. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, Pelletier G (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24: 152–182

    Article  PubMed  CAS  Google Scholar 

  9. Recchione C, Venturelli E, Manzari A, Cavalleri A, Martinetti A, Secreto G (1995) Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. J Steroid Biochem Mol Biol 52:541–546

    Article  PubMed  CAS  Google Scholar 

  10. Shibuya R, Suzuki T, Miki Y, Yoshida K, Moriya T, Ono K, Akahira JI, Ishida T, Hirakawa H, Evans DB, Sasano H (2008) Intratumoral concentration of sex steroids and expression of sex steroidproducing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer 15:113–124

    Article  PubMed  CAS  Google Scholar 

  11. Mindnich R, Moller G, Adamski J (2004) The role of 17betahydroxysteroid dehydrogenases. Mol Cell Endocrinol 218:7–20

    Article  PubMed  CAS  Google Scholar 

  12. Nagasaki S, Miki Y, Akahira J, Suzuki T, Sasano H (2009) 17betahydroxysteroid dehydrogenases in human breast cancer. Ann N Y Acad Sci 55:25–32

    Article  CAS  Google Scholar 

  13. Dufort I, Rheault P, Huang XF, Soucy P. Luu-The V (1999) Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 140:568–574

    Article  PubMed  CAS  Google Scholar 

  14. Penning TM, Burczynski ME, Jez JM, Lin HK, Ma H, Moore M, Ratnam K, Palackal N (2001) Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). Mol Cell Endocrinol 171:137–149

    Article  PubMed  CAS  Google Scholar 

  15. Ji Q, Aoyama C, Nien YD, Liu PI, Chen PK, Chang L, Stanczyk FZ, Stolz A (2004) Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res 64:7610–7617

    Article  PubMed  CAS  Google Scholar 

  16. Oduwole OO, Li Y, Isomaa VV, Mäntyniemi A, Pulkka AE, Soini Y, Vihko PT (2004) 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 15:7604–609

    Article  Google Scholar 

  17. Vihko P, Herrala A, Harkonen P, Isomaa V, Kaija H, Kurkela R, Li Y, Patrikainen L, Pulkka A, Soronen P, Torn S (2005) Enzymes as modulators in malignant transformation. J Steroid Biochem Mol Biol 93:277–283

    Article  PubMed  CAS  Google Scholar 

  18. Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T, Sasano H (2001) 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J Clin Endocrinol Metab 86:2250–2257

    Article  PubMed  CAS  Google Scholar 

  19. Han B, Li S, Song D, Poisson-Paré D, Liu G, Luu-The V, Ouellet J, Li S, Labrie F, Pelletier G (2008) Expression of 17betahydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters. J Steroid Biochem Mol Biol 112:194–200

    Article  PubMed  CAS  Google Scholar 

  20. Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N, Sasano H (2005) Sex-steroid producing enzymes in human breast cancer. Endocr Relat Cancer 12:701–720

    Article  PubMed  CAS  Google Scholar 

  21. Luu-The V, Dufort I, Pelletier G, Labrie F (2001) Type 5 17betahydroxysteroid dehydrogenase: its role in the formation of androgens in women. Mol Cell Endocrinol 171:77–82

    Article  PubMed  CAS  Google Scholar 

  22. Wiebe JP, Muzia D, Hu J, Szwajcer D, Hill SA, Seachrist JL (2000) The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res 60: 936–943

    PubMed  CAS  Google Scholar 

  23. Suzuki T, Murry BA, Darnel AD, Sasano H (2002) Progesterone metabolism in human leukemic monoblast U937 cells. Endocr J 49:539–546

    Article  PubMed  CAS  Google Scholar 

  24. Wiebe JP, Souter L, Zhang G (2006) Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment. J Steroid Biochem Mol Biol 100:129–140

    Article  PubMed  CAS  Google Scholar 

  25. Mistry P, Griffiths K, Maynard PV (1986) Endogenous C19-steroids and oestradiol levels in human primary breast tumour tissues and their correlation with androgen and oestrogen receptors. J Steroid Biochem 24:1117–1125

    Article  PubMed  CAS  Google Scholar 

  26. Spinola PG, Marchetti B, Merand Y, Belanger A, Labrie F (1988) Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors. Breast Cancer Res Treat 12: 287–296

    Article  PubMed  CAS  Google Scholar 

  27. Sonne-Hansen K, Lykkesfeldt AE (2005) Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. J Steroid Biochem Mol Biol 93:25–34

    Article  PubMed  CAS  Google Scholar 

  28. Suzuki T, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S, Sasano H (2007) 5alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int J Cancer 20:285–291

    Article  CAS  Google Scholar 

  29. Baum M (2004) Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control 11:217–221

    PubMed  Google Scholar 

  30. Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, Moriya T, Hirakawa H, Evans DB, Hayashi S, Ohuchi N, Sasano H (2007) Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 67:3945–3954

    Article  PubMed  CAS  Google Scholar 

  31. Suzuki T, Miki Y, Moriya T, Akahira J, Hirakawa H, Ohuchi N, Sasano H (2007) In situ production of sex steroids in human breast carcinoma. Med Mol Morphol 40:121–127

    Article  PubMed  CAS  Google Scholar 

  32. Poulin R, Baker D, Labrie F (1988) Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 12: 213–225

    Article  PubMed  CAS  Google Scholar 

  33. de Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F (1991) Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16′α-chloro-3′,17β-dihydroxy-estra-1′,3′,5′-(10′)triene-7′α-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 51:2797–2802

    PubMed  Google Scholar 

  34. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, Lanzino M (2002) Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 193:121–128

    Article  PubMed  CAS  Google Scholar 

  35. Lapointe J, Labrie C (2001) Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology 142:4331–4338

    Article  PubMed  CAS  Google Scholar 

  36. Dauvois S, Geng CS, Levesque C, Merand Y, Labrie F (1991) Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res 51:3131–3135

    PubMed  CAS  Google Scholar 

  37. Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A (2006) Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 66:7775–7782

    Article  PubMed  CAS  Google Scholar 

  38. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD (1995) Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 52:459–467

    Article  PubMed  CAS  Google Scholar 

  39. Zhang J, Sun Y, Liu Y, Sun Y, Liao DJ (2004) Synergistic effects of androgen and estrogen on the mouse uterus and mammary gland. Oncol Rep 12:709–716

    PubMed  CAS  Google Scholar 

  40. Hall RE, Aspinall JO, Horsfall DJ, Birrell SN, Bentel JM, Sutherland RL, Tilley WD (1996) Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. Br J Cancer 74:1175–1180

    PubMed  CAS  Google Scholar 

  41. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ (1984) Androgen receptors in breast cancer. Cancer (Phila) 54:2436–2440

    Article  CAS  Google Scholar 

  42. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Birrell SN, Coetzee GA, Sutherland RL, Butler LM, Tilley WD (2009) Androgen receptor inhibits estrogen receptoralpha activity and is prognostic in breast cancer. Cancer Res 69:6131–6140

    Article  PubMed  CAS  Google Scholar 

  43. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA (2000) Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 167:139–150

    Article  PubMed  CAS  Google Scholar 

  44. Lanzino M, De Amicis F, McPhaul MJ, Marsico S, Panno ML, Andò S (2005) Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells. J Biol Chem 280: 20421–20430

    Article  PubMed  CAS  Google Scholar 

  45. Selim AG, El-Ayat G, Wells CA (2002) Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors. J Clin Pathol 55:14–16

    PubMed  CAS  Google Scholar 

  46. Baqai T, Shousha S (2003) Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast. Histopathology (Oxf) 42:440–447

    Article  CAS  Google Scholar 

  47. Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ (2008) Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 98:137–142

    Article  PubMed  CAS  Google Scholar 

  48. Rody A, Diallo R, Poremba C, Wuelfing P, Kissler S, Solbach C, Kaufmann M, Jackisch C (2005) Androgen receptor expression in ductal carcinoma in situ of the breast: not a helpful marker for classification such as estrogen receptor alpha and progesterone receptor. Appl Immunohistochem Mol Morphol 213:25–29

    Google Scholar 

  49. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120:725–731

    Article  PubMed  CAS  Google Scholar 

  50. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer (Phila) 109:25–32

    Article  CAS  Google Scholar 

  51. Conzen SD (2008) Minireview: nuclear receptors and breast cancer. Mol Endocrinol 22:2215–2228

    Article  PubMed  CAS  Google Scholar 

  52. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature (Lond) 406:747–752

    Article  CAS  Google Scholar 

  53. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874

    Article  PubMed  Google Scholar 

  54. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423

    Article  PubMed  CAS  Google Scholar 

  55. Moriya T, Kasajima A, Ishida K, Kariya Y, Akahira J, Endoh M, Watanabe M, Sasano H (2006) New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med Mol Morphol 39:8–13

    Article  PubMed  CAS  Google Scholar 

  56. Dawson SJ, Provenzano E, Caldas C (2009) Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 45(suppl 1):27–40

    Article  PubMed  Google Scholar 

  57. Linn SC, Van’t Veer LJ (2009) Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer 45(suppl 1):11–26

    Article  PubMed  Google Scholar 

  58. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24:4660–4671

    Article  PubMed  CAS  Google Scholar 

  59. Wells CA, El-Ayat GA (2007) Non-operative breast pathology: apocrine lesions. J Clin Pathol 60:1313–1320

    Article  PubMed  CAS  Google Scholar 

  60. Miller WR, Telford J, Dixon JM, Shivas AA (1985) Androgen metabolism and apocrine differentiation in human breast cancer. Breast Cancer Res Treat 5:67–73

    Article  PubMed  CAS  Google Scholar 

  61. Celis JE, Cabezón T, Moreira JM, Gromov P, Gromova I, Timmermans-Wielenga V, Iwase T, Akiyama F, Honma N, Rank F (2009) Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort. Mol Oncol 3: 220–237

    Article  CAS  Google Scholar 

  62. Japaze H, Emina J, Diaz C, Schwam RJ, Gercovich N, Demonty G, Morgenfeld E, Rivarola E, Gil Deza E, Gercovich FG (2005) “Pure” invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast 14:3–10

    Article  PubMed  CAS  Google Scholar 

  63. Celis JE, Gromov P, Cabezón T, Moreira JM, Friis E, Jirström K, Llombart-Bosch A, Timmermans-Wielenga V, Rank F, Gromova I (2008) 15-Prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol Cell Proteomics 7:1795–1809

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan

    Takashi Suzuki & Kiyoshi Takagi

  2. Department of Anatomic Pathology, Tohoku Kosai Hospital, Sendai, Japan

    Yasuhiro Miki & Hironobu Sasano

  3. Department of Surgery, Tohoku Kosai Hospital, Sendai, Japan

    Hisashi Hirakawa

  4. Department of Pathology 2, Kawasaki Medical School, Kurashiki, Japan

    Takuya Moriya

  5. Department of Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan

    Noriaki Ohuchi

Authors
  1. Takashi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuhiro Miki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kiyoshi Takagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hisashi Hirakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuya Moriya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Noriaki Ohuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hironobu Sasano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takashi Suzuki.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Suzuki, T., Miki, Y., Takagi, K. et al. Androgens in human breast carcinoma. Med Mol Morphol 43, 75–81 (2010). https://doi.org/10.1007/s00795-010-0494-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00795-010-0494-3

Key words

  • Androgen
  • Androgen receptor
  • Aromatase
  • Breast cancer
  • Estrogen receptor
  • 5α-Reductase